Market research
ENTA Enanta Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 392M
- P/E ratio
- Not available
- Analyst target
- 21.1667
- Dividend yield
- Not available
- Beta
- 0.93
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US29251M1062
- Market cap
- 392M
- P/E ratio
- Not available
- Analyst target
- 21.1667
- Dividend yield
- Not available
- Beta
- 0.93
About
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ENTA discussion.
5 years, 4 months ago
Enanta Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 8.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.0.
Enanta Pharmaceuticals, Inc's total revenue sank by 39.6% to $32M since the same quarter in the previous year.
Its net income has dropped by 162.0% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 227.0% to $-15M since the same quarter in the previous year.
Based on the above factors, Enanta Pharmaceuticals, Inc gets an overall score of 1/5.